Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

QNCX

Quince Therapeutics (QNCX)

Quince Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:QNCX
DatumZeitQuelleÜberschriftSymbolFirma
27/12/202422h01Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:QNCXQuince Therapeutics Inc
27/12/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:QNCXQuince Therapeutics Inc
18/12/202422h03Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:QNCXQuince Therapeutics Inc
14/11/202412h55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QNCXQuince Therapeutics Inc
14/11/202403h17Edgar (US Regulatory)Form SC 13D - General Statement of Acquisition of Beneficial OwnershipNASDAQ:QNCXQuince Therapeutics Inc
13/11/202423h09Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:QNCXQuince Therapeutics Inc
13/11/202422h05Business WireQuince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial ResultsNASDAQ:QNCXQuince Therapeutics Inc
12/11/202422h05Business WireQuince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia ResearchNASDAQ:QNCXQuince Therapeutics Inc
11/11/202422h05Business WireQuince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual MeetingNASDAQ:QNCXQuince Therapeutics Inc
14/10/202422h05Business WireQuince Therapeutics to Participate at Upcoming Investor ConferencesNASDAQ:QNCXQuince Therapeutics Inc
03/09/202422h05Business WireQuince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:QNCXQuince Therapeutics Inc
22/08/202400h38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QNCXQuince Therapeutics Inc
15/08/202413h00Business WireQuince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)NASDAQ:QNCXQuince Therapeutics Inc
13/08/202422h11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:QNCXQuince Therapeutics Inc
13/08/202422h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QNCXQuince Therapeutics Inc
13/08/202422h05Business WireQuince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial ResultsNASDAQ:QNCXQuince Therapeutics Inc
25/06/202413h00Business WireQuince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-TelangiectasiaNASDAQ:QNCXQuince Therapeutics Inc
08/06/202403h08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QNCXQuince Therapeutics Inc
08/06/202403h04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QNCXQuince Therapeutics Inc
08/06/202402h59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QNCXQuince Therapeutics Inc
06/06/202423h17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QNCXQuince Therapeutics Inc
05/06/202420h37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QNCXQuince Therapeutics Inc
03/06/202413h00Business WireQuince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex SystemNASDAQ:QNCXQuince Therapeutics Inc
13/05/202413h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:QNCXQuince Therapeutics Inc
13/05/202413h00Business WireQuince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial ResultsNASDAQ:QNCXQuince Therapeutics Inc
06/05/202422h05Business WireQuince Therapeutics to Present at The Citizens JMP Life Sciences ConferenceNASDAQ:QNCXQuince Therapeutics Inc
01/04/202413h00Business WireQuince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial ResultsNASDAQ:QNCXQuince Therapeutics Inc
22/02/202413h00Business WireQuince Therapeutics Launches Scientific Advisory BoardNASDAQ:QNCXQuince Therapeutics Inc
15/02/202422h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QNCXQuince Therapeutics Inc
15/02/202413h00Business WireQuince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of DirectorsNASDAQ:QNCXQuince Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:QNCX